ESSA Pharma Ownership
| EPIX Stock | USD 1.79 0.02 1.10% |
Shares in Circulation | First Issued 2013-12-31 | Previous Quarter 44.2 M | Current Value 44.4 M | Avarage Shares Outstanding 18.5 M | Quarterly Volatility 18.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ESSA |
ESSA Stock Ownership Analysis
About 81.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. ESSA Pharma recorded a loss per share of 0.62. The entity last dividend was issued on the 25th of April 2018. The firm had 1:20 split on the 25th of April 2018. ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Essa Pharma is traded on NASDAQ Exchange in the United States. To learn more about ESSA Pharma call David MD at 778 331 0962 or check out https://www.essapharma.com.Besides selling stocks to institutional investors, ESSA Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ESSA Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ESSA Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ESSA Pharma Quarterly Liabilities And Stockholders Equity |
|
Roughly 2.0% of ESSA Pharma are currently held by insiders. Unlike ESSA Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ESSA Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ESSA Pharma's insider trades
ESSA Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ESSA Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ESSA Pharma backward and forwards among themselves. ESSA Pharma's institutional investor refers to the entity that pools money to purchase ESSA Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Parkman Healthcare Partners Llc | 2024-06-30 | 252.1 K | Cibc World Markets Inc. | 2024-06-30 | 80.3 K | D. E. Shaw & Co Lp | 2024-09-30 | 63 K | American Century Companies Inc | 2024-09-30 | 46.7 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 43.6 K | Kennedy Capital Management Inc | 2024-09-30 | 41.1 K | Royal Bank Of Canada | 2024-06-30 | 36.3 K | Citadel Advisors Llc | 2024-09-30 | 28.5 K | Geode Capital Management, Llc | 2024-09-30 | 26.9 K | Bvf Inc | 2024-09-30 | 8.7 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 8.4 M |
ESSA Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ESSA Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ESSA Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ESSA Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ESSA Pharma Outstanding Bonds
ESSA Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ESSA Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ESSA bonds can be classified according to their maturity, which is the date when ESSA Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.